RHEUMATOID FACTOR--GENETICS, PATHOGENESIS AND MODULATION
类风湿因子——遗传学、发病机制和调节
基本信息
- 批准号:2078544
- 负责人:
- 金额:$ 24.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1990
- 资助国家:美国
- 起止时间:1990-09-15 至 1999-05-31
- 项目状态:已结题
- 来源:
- 关键词:B lymphocyte Epstein Barr virus antibody formation autoantibody autoimmune disorder histocompatibility antigens human subject hybridomas immune complex immunoglobulin genes immunoglobulin idiotypes laboratory mouse laboratory rabbit monoclonal antibody radioimmunoassay rheumatoid arthritis rheumatoid factor synovial fluid
项目摘要
Rheumatoid arthritis is a chronic inflammatory disease that primarily
affects the joints. IgM and IgG autoantibodies reactive with the Fc
fragment of IgG (rheumatoid factors, RF) are the hallmark of the disease.
Understanding the structural and genetic basis for RF synthesis, and the
reasons for sustained RF production in rheumatoid arthritis, is the long
term objective of this research grant proposal. We have characterized
antibodies that identify both variable region subgroups, and cross-reactive
idiotypes (CRIs) on RFs, and have demonstrated that the light chains on
monoclonal RFs from unrelated people are structurally related. Two V kappa
genes (Humkv325 and Humkv328) that can encode human RF light chains were
isolated and sequenced. The Humkv325 gene is utilized repeated in chronic
lymphocytic leukemia, a lymphoproliferative disease that is often
associated with autoantibody production. Other experiments revealed that
IgM RF precursors are abundant in the blood and bone marrow of normal
people, despite the absence of overt RF synthesis. Transient expansion of
the IgM RF precursor cell pool regularly accompanies anamnestic immune
responses. In rheumatoid arthritis, therefore, it is aberrant regulation
of RF synthesis and diversification that is fundamental to the disease
process, rather than the mere presence of the autoantibody. The proposed
experiments intend to determine the causes of the abnormal regulation and
to devise methods to overcome it. The specific aims of the experiments
are: (1) to define the structural and genetic basis for three distinct
CRIs on human monoclonal RF heavy chains; (2) to characterize the idiotypes
and genes used for polyclonal RF synthesis in the blood and synovium of
patients with rheumatoid arthritis; (3) to clarify the physiologic function
of the RF CRI precursor B cells, by studying their distribution in lymphoid
organs, their utilization in antibody responses against exogenous antigens,
and their role in the processing of antigen-antibody complexes; (4) to
discern how the HLA DR antigens Dw4 and DR1 may predispose to abnormally
sustained RF production following exposure to an environmental antigen
(Epstein-Barr virus gp110) that reproduces the rheumatoid arthritis
susceptibility determinant in the DR beta-1 chain; and (5) to develop
therapies that can prevent or terminate RF autoantibody production in
experimental animals, and eventually in patients with rheumatoid arthritis
and other RF-associated illnesses.
类风湿关节炎是一种慢性炎症性疾病,主要
影响关节。与Fc反应的IgM和Ig G自身抗体
免疫球蛋白片段(类风湿因子,RF)是该病的标志。
了解射频合成的结构和遗传基础,以及
类风湿关节炎持续产生RF的原因,是长期的
这项研究资助提案的学期目标。我们已经刻画了
识别可变区亚群和交叉反应的抗体
RFS上的独特型(CRI),并证明了轻链上的
来自无关人群的单克隆性RFs在结构上是相关的。两个V卡帕
能够编码人类RF轻链的基因(Humkv325和Humkv328)是
分离并测序。Humkv325基因在慢性阻塞性肺疾病中的重复利用
淋巴细胞性白血病是一种淋巴增生性疾病,通常
与自身抗体的产生有关。其他实验表明,
正常人血液和骨髓中有丰富的IgM-RF前体
人们,尽管没有公开的射频合成。瞬时膨胀
免疫球蛋白M型RF前体细胞池经常伴随有记忆免疫
回应。因此,在类风湿性关节炎中,这是一种异常的调节。
射频合成和多样化是该病的基础
过程,而不仅仅是自身抗体的存在。建议数
实验意在确定异常调节的原因和
想出克服它的方法。这些实验的具体目的
主要有:(1)明确了三种不同的结构和遗传基础
人单克隆性RF重链上的CRIS;(2)独特型的鉴定
以及血液和滑膜中用于多克隆RF合成的基因
类风湿性关节炎患者;(3)明确生理功能
通过研究RF CRI前体B细胞在淋巴中的分布
器官,它们在对外源抗原的抗体反应中的利用,
以及它们在抗原-抗体复合体加工过程中的作用;
辨别HLADR抗原Dw4和Dr1是如何诱发异常的
暴露于环境抗原后持续的射频产生
(Epstein-Barr病毒gp110)复制类风湿性关节炎
DRβ-1链中的易感决定因素;以及(5)发展
可以预防或终止RF自身抗体产生的治疗方法
实验动物,最终用于类风湿性关节炎患者
以及其他与射频相关的疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(17)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DENNIS CARSON其他文献
DENNIS CARSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DENNIS CARSON', 18)}}的其他基金
Tetrahydrothieno[2,3-c]pyridines as Vaccine Co-adjuvants
四氢噻吩并[2,3-c]吡啶作为疫苗辅佐剂
- 批准号:
10307634 - 财政年份:2020
- 资助金额:
$ 24.24万 - 项目类别:
Discovery of agents that induce exosomes with adjuvant activity
发现具有佐剂活性的外泌体诱导剂
- 批准号:
10027065 - 财政年份:2019
- 资助金额:
$ 24.24万 - 项目类别:
Discovery of agents that induce exosomes with adjuvant activity
发现具有佐剂活性的外泌体诱导剂
- 批准号:
10452468 - 财政年份:2019
- 资助金额:
$ 24.24万 - 项目类别:
Discovery of agents that induce exosomes with adjuvant activity
发现具有佐剂活性的外泌体诱导剂
- 批准号:
10642649 - 财政年份:2019
- 资助金额:
$ 24.24万 - 项目类别:
Discovery of agents that induce exosomes with adjuvant activity
发现具有佐剂活性的外泌体诱导剂
- 批准号:
10166664 - 财政年份:2019
- 资助金额:
$ 24.24万 - 项目类别:
TO IDENTIFY NOVEL ADJUVANT CANDIDATES THAT CAN BE USED TO AUGMENT THE EFFICACY OF HUMAN VACCINES.
确定可用于增强人类疫苗功效的新型佐剂候选物。
- 批准号:
10706867 - 财政年份:2019
- 资助金额:
$ 24.24万 - 项目类别:
Discovery of agents that induce exosomes with adjuvant activity
发现具有佐剂活性的外泌体诱导剂
- 批准号:
10834814 - 财政年份:2019
- 资助金额:
$ 24.24万 - 项目类别:
Adjuvant Discovery for Vaccines against West Nile Virus and Influenza
西尼罗河病毒和流感疫苗的佐剂发现
- 批准号:
9547196 - 财政年份:2014
- 资助金额:
$ 24.24万 - 项目类别:
Adjuvant Discovery for Vaccines against West Nile Virus and Influenza
西尼罗河病毒和流感疫苗的佐剂发现
- 批准号:
8937388 - 财政年份:2014
- 资助金额:
$ 24.24万 - 项目类别:
Adjuvant Discovery for Vaccines against West Nile Virus and Influenza
西尼罗河病毒和流感疫苗的佐剂发现
- 批准号:
9120714 - 财政年份:2014
- 资助金额:
$ 24.24万 - 项目类别:
相似海外基金
Project 4 - Controlling the Latent-to-Lytic Switch in Epstein-Barr Virus
项目 4 - 控制 Epstein-Barr 病毒中的潜伏至裂解转换
- 批准号:
10910338 - 财政年份:2023
- 资助金额:
$ 24.24万 - 项目类别:
Epstein-Barr Virus nuclear antigen leader protein in transcription regulation
Epstein-Barr病毒核抗原前导蛋白在转录调控中的作用
- 批准号:
10829620 - 财政年份:2023
- 资助金额:
$ 24.24万 - 项目类别:
Exploiting Metabolism to Uncloak Epstein-Barr Virus Immunogens in Latently Infected B-cells
利用代谢揭示潜伏感染 B 细胞中的 Epstein-Barr 病毒免疫原
- 批准号:
10889325 - 财政年份:2023
- 资助金额:
$ 24.24万 - 项目类别:
Understanding the immune response changes to clinical interventions for Epstein-Barr virus infection prior to lymphoma development in children after organ transplants (UNEARTH)
了解器官移植后儿童淋巴瘤发展之前针对 Epstein-Barr 病毒感染的临床干预的免疫反应变化(UNEARTH)
- 批准号:
10755205 - 财政年份:2023
- 资助金额:
$ 24.24万 - 项目类别:
Regulation and Functions of the Epstein-Barr Virus Lytic Switch Protein
EB 病毒裂解开关蛋白的调控和功能
- 批准号:
489085 - 财政年份:2023
- 资助金额:
$ 24.24万 - 项目类别:
Operating Grants
Characterization of Epstein-Barr Virus Subversion of the Host SMC5/6 Restriction Pathway
Epstein-Barr 病毒颠覆宿主 SMC5/6 限制途径的特征
- 批准号:
10679118 - 财政年份:2023
- 资助金额:
$ 24.24万 - 项目类别:
Deciphering the Role of Epstein-Barr Virus Molecular Mimicry and B cell Transformation in Multiple Sclerosis
解读 Epstein-Barr 病毒分子拟态和 B 细胞转化在多发性硬化症中的作用
- 批准号:
10568864 - 财政年份:2023
- 资助金额:
$ 24.24万 - 项目类别:
Epstein Barr Virus Driven Mechanisms of Post Transplant Lymphoproliferative Disease
EB 病毒驱动的移植后淋巴增殖性疾病的机制
- 批准号:
10755055 - 财政年份:2023
- 资助金额:
$ 24.24万 - 项目类别:
Project 2: Novel investigation of Epstein-Barr virus as a potential cause of conjunctival squamous cell carcinoma among people living with HIV in Zimbabwe
项目 2:对 Epstein-Barr 病毒作为津巴布韦艾滋病毒感染者结膜鳞状细胞癌潜在原因的新调查
- 批准号:
10598376 - 财政年份:2023
- 资助金额:
$ 24.24万 - 项目类别:
Project 3 - Characterizing the Amplification Factories of Epstein-Barr Virus and Kaposi's Sarcoma-associated Herpesvirus
项目 3 - 描述 Epstein-Barr 病毒和卡波西肉瘤相关疱疹病毒的扩增工厂
- 批准号:
10910337 - 财政年份:2023
- 资助金额:
$ 24.24万 - 项目类别:














{{item.name}}会员




